Business Description
Strides Pharma Science Ltd
ISIN : INE939A01011
Compare
Compare
Traded in other countries / regions
STAR.India IPO Date
2000-02-02Description
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market planĀ focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth planĀ for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.15 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.02 | |||||
| Debt-to-EBITDA | 3.21 | |||||
| Interest Coverage | 2.27 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.42 | |||||
| Beneish M-Score | -3.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.6 | |||||
| 3-Year EBITDA Growth Rate | -15.5 | |||||
| 3-Year FCF Growth Rate | 46.1 | |||||
| 3-Year Book Growth Rate | -9.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.82 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.21 | |||||
| 9-Day RSI | 69.66 | |||||
| 14-Day RSI | 64.39 | |||||
| 6-1 Month Momentum % | 76.7 | |||||
| 12-1 Month Momentum % | 207.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | |||||
| Quick Ratio | 0.64 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 229.68 | |||||
| Days Sales Outstanding | 103.37 | |||||
| Days Payable | 180.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.15 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| 3-Year Dividend Growth Rate | -9.1 | |||||
| Forward Dividend Yield % | 0.15 | |||||
| 5-Year Yield-on-Cost % | 0.15 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 3.47 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.7 | |||||
| Operating Margin % | 14.96 | |||||
| Net Margin % | 5.44 | |||||
| FCF Margin % | 13.71 | |||||
| ROE % | 10.76 | |||||
| ROA % | 3.82 | |||||
| ROIC % | 9.3 | |||||
| ROC (Joel Greenblatt) % | 21.3 | |||||
| ROCE % | 16.98 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 64.92 | |||||
| Forward PE Ratio | 32.14 | |||||
| PE Ratio without NRI | 86.63 | |||||
| Shiller PE Ratio | 73.37 | |||||
| PS Ratio | 3.54 | |||||
| PB Ratio | 6.62 | |||||
| Price-to-Tangible-Book | 13.19 | |||||
| Price-to-Free-Cash-Flow | 25.57 | |||||
| Price-to-Operating-Cash-Flow | 21.26 | |||||
| EV-to-EBIT | 32.78 | |||||
| EV-to-EBITDA | 23.67 | |||||
| EV-to-Revenue | 4.01 | |||||
| EV-to-FCF | 29.24 | |||||
| Price-to-Projected-FCF | 9.75 | |||||
| Price-to-Median-PS-Value | 1.79 | |||||
| Price-to-Graham-Number | 7.13 | |||||
| Earnings Yield (Greenblatt) % | 3.05 | |||||
| FCF Yield % | 3.87 | |||||
| Forward Rate of Return (Yacktman) % | -6.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Strides Pharma Science Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ā¹) | 42,502.15 | ||
| EPS (TTM) (ā¹) | 25.19 | ||
| Beta | 1.36 | ||
| Volatility % | 35.57 | ||
| 14-Day RSI | 64.39 | ||
| 14-Day ATR (ā¹) | 71.414109 | ||
| 20-Day SMA (ā¹) | 1485.3925 | ||
| 12-1 Month Momentum % | 207.29 | ||
| 52-Week Range (ā¹) | 482 - 1675 | ||
| Shares Outstanding (Mil) | 92.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Strides Pharma Science Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Strides Pharma Science Ltd Stock Events
| Event | Date | Price(ā¹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Strides Pharma Science Ltd Frequently Asked Questions
What is Strides Pharma Science Ltd(NSE:STAR)'s stock price today?
The current price of NSE:STAR is ā¹1635.35. The 52 week high of NSE:STAR is ā¹1675.00 and 52 week low is ā¹482.00.
When is next earnings date of Strides Pharma Science Ltd(NSE:STAR)?
The next earnings date of Strides Pharma Science Ltd(NSE:STAR) is .
Does Strides Pharma Science Ltd(NSE:STAR) pay dividends? If so, how much?
TheĀ Dividend Yield % Ā of Strides Pharma Science Ltd(NSE:STAR) is 0.15% (As of Today), HighestĀ Dividend Payout RatioĀ of Strides Pharma Science Ltd(NSE:STAR) was 4.54. The lowest was 0.09. And the median was 0.47. The Ā Forward Dividend Yield % of Strides Pharma Science Ltd(NSE:STAR) is 0.15%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers